Ronen Tsimerman - 18 Mar 2026 Form 3 Insider Report for IceCure Medical Ltd. (ICCM)

Reporting relationship: Chief Financial Officer
Issuer ticker: ICCM
Reported as of: 18 Mar 2026
Net transaction value: $0
SEC form: 3
Accepted by SEC: 25 Mar 2026, 17:12:47 UTC
Next SEC filing: 18 May 2026
Source filing: View source filing
Reporting owner signature: /s/ Ronen Tsimerman

Key filing fact

Ronen Tsimerman filed Form 3 for IceCure Medical Ltd. (ICCM) on 25 Mar 2026.

Key facts

This page summarizes Ronen Tsimerman's Form 3 filing for IceCure Medical Ltd. (ICCM).
0 reported transactions and 10 derivative rows are listed below.
Accepted by SEC: 25 Mar 2026, 17:12.

Change

No earlier filing in this sequence is available for direct comparison.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Official SEC source

Ownership activity is grounded in SEC Form 3 disclosures.

View source filing

Reporting Owners (1)

CIK 0002046680 Primary reporting owner

Tsimerman Ronen

Relationship: Chief Financial Officer
Address: 7 HA'ESHEL ST., PO BOX 3163, CAESAREA, ISRAEL
Signature: /s/ Ronen Tsimerman
Signature date: 25 Mar 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ICCM holding

Ordinary shares

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 177,949
Date: 18 Mar 2026
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ICCM holding Derivative

Share option (right to buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 18 Mar 2026
Ownership: Direct
Underlying class: Ordinary shares
Underlying amount: 83,610
Exercise price: $0.7900
Footnotes: F2, F3

ICCM holding Derivative

Share option (right to buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 18 Mar 2026
Ownership: Direct
Underlying class: Ordinary shares
Underlying amount: 75,000
Exercise price: $2.09
Footnotes: F4, F5

ICCM holding Derivative

Share option (right to buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 18 Mar 2026
Ownership: Direct
Underlying class: Ordinary shares
Underlying amount: 4,549
Exercise price: $2.27
Footnotes: F6, F7

ICCM holding Derivative

Share option (right to buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 18 Mar 2026
Ownership: Direct
Underlying class: Ordinary shares
Underlying amount: 16,000
Exercise price: $1.79
Footnotes: F8, F9

ICCM holding Derivative

Share option (right to buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 18 Mar 2026
Ownership: Direct
Underlying class: Ordinary shares
Underlying amount: 28,833
Exercise price: $1.56
Footnotes: F10, F11

ICCM holding Derivative

Share option (right to buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 18 Mar 2026
Ownership: Direct
Underlying class: Ordinary shares
Underlying amount: 1,537
Exercise price: $5.78
Footnotes: F12, F13

ICCM holding Derivative

Share option (right to buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 18 Mar 2026
Ownership: Direct
Underlying class: Ordinary shares
Underlying amount: 121,002
Exercise price: $3.64
Footnotes: F14, F15

ICCM holding Derivative

Share option (right to buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 18 Mar 2026
Ownership: Direct
Underlying class: Ordinary shares
Underlying amount: 4,802
Exercise price: $2.84
Footnotes: F16, F17

ICCM holding Derivative

Share option (right to buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 18 Mar 2026
Ownership: Direct
Underlying class: Ordinary shares
Underlying amount: 48,846
Exercise price: $1.51
Footnotes: F18, F19

ICCM holding Derivative

Share option (right to buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 18 Mar 2026
Ownership: Direct
Underlying class: Ordinary shares
Underlying amount: 127,322
Exercise price: $0.9200
Footnotes: F20

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 20 footnotes

Footnote F1

Represents (i) 16,257 ordinary shares, (ii) 106,102 restricted share units ("RSUs") granted on July 2, 2024, 25% of which vest on July 29, 2026 and the remaining 75% vest in equal quarterly installments of 6.25% thereafter, all of which remain unvested as of March 18, 2026, and (iii) 55,590 RSUs granted on November 5, 2025, 25% of which vest on November 5, 2026 and the remaining 75% vest in equal quarterly installments of 6.25% thereafter, all of which remain unvested as of March 18, 2026.

Footnote F2

A total of 95,555 options were granted on May 23, 2017, and vested in equal quarterly installments of 6.25% beginning May 1, 2017. As of March 18, 2026, 83,610 options are fully vested and 11,945 have been exercised into ordinary shares.

Footnote F3

The options were granted with an exercise price of NIS 2.448 per share. For purposes of this Form 3, the exercise price has been converted into U.S. dollars using an exchange rate of NIS 3.10 to USD $1.00 as of March 11, 2026, resulting in an exercise price of $0.79 per share.

Footnote F4

The options were granted on August 14, 2018, 25% of which vested on August 14, 2019, and the remaining 75% vested in equal quarterly installments of 6.25% thereafter. As of March 18, 2026, all 75,000 options are fully vested.

Footnote F5

The options were granted with an exercise price of NIS 6.472 per share. For purposes of this Form 3, the exercise price has been converted into U.S. dollars using an exchange rate of NIS 3.10 to USD $1.00 as of March 11, 2026, resulting in an exercise price of $2.09 per share.

Footnote F6

The options were granted on March 28, 2019, 25% of which vested on March 28, 2020, and the remaining 75% vested in equal quarterly installments of 6.25% thereafter. As of March 18, 2026, all 4,549 options are fully vested.

Footnote F7

The options were granted with an exercise price of NIS 7.04 per share. For purposes of this Form 3, the exercise price has been converted into U.S. dollars using an exchange rate of NIS 3.10 to USD $1.00 as of March 11, 2026, resulting in an exercise price of $2.27 per share.

Footnote F8

The options were granted on May 21, 2019, and vested in equal quarterly installments of 6.25% beginning on May 21, 2019. As of March 18, 2026, all 16,000 options are fully vested.

Footnote F9

The options were granted with an exercise price of NIS 5.536 per share. For purposes of this Form 3, the exercise price has been converted into U.S. dollars using an exchange rate of NIS 3.10 to USD $1.00 as of March 11, 2026, resulting in an exercise price of $1.79 per share.

Footnote F10

The options were granted on August 30, 2020, 25% of which vested on August 30, 2021, and the remaining 75% vested in equal quarterly installments of 6.25% thereafter. As of March 18, 2026, all 28,833 options are fully vested.

Footnote F11

The options were granted with an exercise price of NIS 4.84 per share. For purposes of this Form 3, the exercise price has been converted into U.S. dollars using an exchange rate of NIS 3.10 to USD $1.00 as of March 11, 2026, resulting in an exercise price of $1.56 per share.

Footnote F12

The options were granted on April 28, 2021, 25% of which vested on April 28, 2022, and the remaining 75% vested in equal quarterly installments of 6.25% thereafter. As of March 18, 2026, all 1,537 options are fully vested.

Footnote F13

The options were granted with an exercise price of NIS 17.92 per share. For purposes of this Form 3, the exercise price has been converted into U.S. dollars using an exchange rate of NIS 3.10 to USD $1.00 as of March 11, 2026, resulting in an exercise price of $5.78 per share.

Footnote F14

The options were granted on January 12, 2022, 25% of which vested on January 12, 2023, and the remaining 75% vested in equal quarterly installments of 6.25% thereafter. As of March 18, 2026, all 121,002 options are fully vested.

Footnote F15

The options were granted with an exercise price of NIS 11.29 per share. For purposes of this Form 3, the exercise price has been converted into U.S. dollars using an exchange rate of NIS 3.10 to USD $1.00 as of March 11, 2026, resulting in an exercise price of $3.64 per share.

Footnote F16

The options were granted on March 23, 2022, 25% of which vested on March 23, 2023, and the remaining 75% vest in equal quarterly installments of 6.25% thereafter. As of March 18, 2026, 4,501 options are vested.

Footnote F17

The options were granted with an exercise price of NIS 8.81 per share. For purposes of this Form 3, the exercise price has been converted into U.S. dollars using an exchange rate of NIS 3.10 to USD $1.00 as of March 11, 2026, resulting in an exercise price of $2.84 per share.

Footnote F18

The options were granted on February 19, 2023, 25% of which vested on February 19, 2024, and the remaining 75% vest in equal quarterly installments of 6.25% thereafter. As of March 18, 2026, 36,634 options are vested.

Footnote F19

The options were granted with an exercise price of NIS 4.68 per share. For purposes of this Form 3, the exercise price has been converted into U.S. dollars using an exchange rate of NIS 3.10 to USD $1.00 as of March 11, 2026, resulting in an exercise price of $1.51 per share.

Footnote F20

The options were granted on July 2, 2024, 25% of which vested on July 2, 2025, and the remaining 75% vest in equal quarterly installments of 6.25% thereafter. As of March 18, 2026, 47,745 options are vested.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. to update or revoke optional consent for future visits. For more information, see our Privacy Policy .